Abstract:Xiaoju Huang, 1– 3 Mengmeng Wang, 1– 3 Dan Zhang, 1– 3 Junpeng Meng, 4, 5 Pian Liu 1– 3 1 Cancer Center Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, People's Republic of China; 2 Hubei Key Laboratory of Precision Radiation Oncology, Wuhan, 430022, People's Republic of China; 3 Institute of Radiation Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, People's Republic of China; 4 Department of Pancreatic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, People's Republic of China; 5 Department of General Surgery, the Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, 030001, People's Republic of China Correspondence: Pian Liu; Junpeng Meng, Email ; Background: Liver cancer is the sixth most common cancer worldwide, and hepatocellular carcinoma (HCC) presents one of the most challenging global health issues. ZDHHC20, a member of the ZDHHC palmitoyltransferase (ZDHHC-PAT) family, is involved in a reversible lipid modification known as palmitoylation, which contributes to the occurrence and progression of various tumors. However, the specific mechanisms underlying the involvement of ZDHHC20 in this process are unclear. Methods: The effects of both ZDHHC20 knockdown and overexpression on hepatocellular carcinoma cell proliferation were evaluated using PCR, Western blotting, CCK-8 assay, colony formation assay, cell cycle analysis, apoptosis analysis, and EDU assay. The TCGA-LIHC dataset was analyzed bioinformatically, and the phosphorylation level of PI3K and AKT in SK-Hep1 and Huh7 cells was assessed using Western blotting. Nude mouse subcutaneous xenograft experiments were conducted to evaluate the effects of different treatment conditions on mouse tumor growth. Results: ZDHHC20 knockdown inhibited cell proliferation and promoted apoptosis, while overexpression of ZDHHC20 promoted cell proliferation and inhibited apoptosis. Knockdown of ZDHHC20 also decreased phosphorylation of PI3K and AKT in HCC, whereas overexpression of ZDHHC20 increased phosphorylation of PI3K and AKT. The PI3K-AKT pathway inhibitors, LY294002 and MK2206, effectively inhibited the promotional effects of ZDHHC20 on the proliferation and growth of HCC. Conclusion: High expression of ZDHHC20 promotes the proliferation and tumor growth of HCC by activating the PI3K-AKT signaling pathway. The PI3K inhibitor LY294002 and the AKT inhibitor MK2206 inhibit the promotional effects of ZDHHC20 on the proliferation of HCC and the growth of tumors. Keywords: hepatocellular carcinoma, ZDHHC20, PI3K-AKT pathway, cell proliferation Hepatocellular carcinoma (HCC) is one of the most prevalent cancers worldwide. According to 2020 statistics, liver cancer is the sixth most common cancer and the third leading cause of cancer-related death. 1 HCC accounts for approximately 75–85% of primary liver cancer. 2 Unfortunately, most cases of HCC are diagnosed late due to delayed symptoms and lack of early detection, resulting in poor prognosis for patients. Therefore, more in-depth investigation on the mechanisms underlying HCC occurrence, metastasis, and recurrence, as well as the exploration of appropriate targeted interventions, is needed to improve the prognosis for patients with HCC. Palmitoylation is a reversible lipid modification process in which palmitoyl groups are covalently bound by thioester bonds to cysteine by palmitoyl acyltransferase. 3,4 Palmitoylation is catalyzed primarily by the ZDHHC palmitoyl S-acyltransferases (PATs) family of proteins, which are known as DHHC-PAT because of their unique catalytic motif, DHHC (Asp-His-His-Cys). 5 This domain also combines two Zn2+ ions to form a zinc finger domain, resulting in a ZDHHC palmitoyltransferase. To date, 23 human ZDHHC genes (named ZDHHC1–24, without ZDHHC10) have been identified. 6 Although palmitoylation is known to regulate protein localization, stability, and function, the mechanisms by which ZDHHCs select substrate proteins for modification is not fully understood. ZDHHC20 is one of the most extensively studied members of this family and is the only DHHC enzyme with a known spatial structure. 7 Since the discovery of palmitoylation, various proteins have been found to undergo ZDHHC-mediated palmitoylation modification, which is implicated in the occurrence and development of various tumors. A list of 299 cancer driver genes was recently validated, of which 26% may undergo palmitoylation modification. 8 At least 15 of the 23 known human ZDHHCs a -Abstract Truncated-

ZDHHC22-Mediated mTOR Palmitoylation Determines Breast Tumor Growth and Endocrine Therapy Sensitivity

ZDHHC22-mediated mTOR palmitoylation restrains breast cancer growth and endocrine therapy resistance

Palmitoylation landscapes across human cancers reveal a role of palmitoylation in tumorigenesis

Palmitoylation of MDH2 by ZDHHC18 Activates Mitochondrial Respiration and Accelerates Ovarian Cancer Growth

Palmitoylation alters LDHA activity and pancreatic cancer response to chemotherapy

DNA methylation downregulated ZDHHC1 suppresses tumor growth by altering cellular metabolism and inducing oxidative/ER stress-mediated apoptosis and pyroptosis

Methylation of EZH2 by PRMT1 regulates its stability and promotes breast cancer metastasis

Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers.

ZDHHC20 Activates AKT Signaling Pathway to Promote Cell Proliferation in Hepatocellular Carcinoma

ZDHHC20-mediated S-palmitoylation of YTHDF3 stabilizes MYC mRNA to promote pancreatic cancer progression

PRMT1-mediated EZH2 methylation promotes breast cancer cell proliferation and tumorigenesis

USP22 Contributes to Chemoresistance, Stemness, and EMT Phenotype of Triple-Negative Breast Cancer Cells by egulating the Warburg Effect via c-Myc Deubiquitination

Emerging roles of protein palmitoylation and its modifying enzymes in cancer cell signal transduction and cancer therapy

Analysis of N6-Methyladenosine Methyltransferase Reveals METTL14 and ZC3H13 as Tumor Suppressor Genes in Breast Cancer

Cancer Cells Escape P53's Tumor Suppression Through Ablation of ZDHHC1-mediated P53 Palmitoylation

Data from Epigenetic Silencing Mediated Through Activated PI3K/AKT Signaling in Breast Cancer

mTOR complex-2 stimulates acetyl-CoA and de novo lipogenesis through ATP citrate lyase in HER2/PIK3CA-hyperactive breast cancer.

Palmitoyl transferases act as potential regulators of tumor-infiltrating immune cells and glioma progression

Acyltransferase zinc finger DHHC-type containing 2 aggravates gastric carcinoma growth by targeting Nrf2 signaling: A mechanism-based multicombination bionic nano-drug therapy

O-GlcNAcylation of MITF regulates its activity and CDK4/6 inhibitor resistance in breast cancer

DPM2 serve as novel oncogene and prognostic marker transactivated by ESR1 in breast cancer